Hematology

  • HematologyStandard

    Absolute Neutrophil Count (ANC)

    The Absolute Neutrophil Count (ANC) is indicated for bedside clinical practice to support Frequently used to assess febrile neutropenia in chemotherapy patients, by calculating the total number of mature and immature neutrophils. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2006

    4Ts Score for Heparin-Induced Thrombocytopenia

    The 4Ts Score for Heparin-Induced Thrombocytopenia is indicated for bedside clinical practice to support Differentiates patients with heparin-induced thrombocytopenia (HIT) from those with other causes of thrombocytopenia. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2010

    HAS-BLED Score for Major Bleeding Risk

    The HAS-BLED Score for Major Bleeding Risk is indicated for bedside clinical practice to support Estimates 1-year risk of major bleeding for patients on anticoagulation to assess quality of atrial fibrillation care. Used with CHA2DS2-VASc score to balance stroke vs bleeding risk.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2024

    Corrected Reticulocyte Percentage/Reticulocyte Production Index (RPI)

    The Corrected Reticulocyte Percentage/Reticulocyte Production Index (RPI) is indicated for bedside clinical practice to support Assesses bone marrow response to anemia by correcting reticulocyte count for degree of anemia and maturation time. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2001

    ISTH Criteria for Disseminated Intravascular Coagulation (DIC)

    The ISTH Criteria for Disseminated Intravascular Coagulation (DIC) is indicated for bedside clinical practice to support Diagnoses overt disseminated intravascular coagulation (DIC) based on laboratory parameters. This scoring system was developed by the International Society on Thrombosis and Haemostasis (ISTH) as a standardized approach to DIC diagnosis using readily available laboratory tests. Use only in patients with clinical suspicion for DIC in appropriate clinical settings.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2021

    Corrected Count Increment (CCI) for Platelet Transfusion

    The Corrected Count Increment (CCI) for Platelet Transfusion is indicated for bedside clinical practice to support Assesses adequacy of response to platelet transfusion by measuring the expected increase in platelets adjusted for patient size and platelet dose. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2011 Spyropoulos

    IMPROVE Risk Score for Venous Thromboembolism (VTE)

    The IMPROVE Risk Score for Venous Thromboembolism (VTE) is indicated for bedside clinical practice to support Predicts 3-month risk of acute venous thromboembolism (VTE) in hospitalized medical patients. The IMPROVE (International Medical Prevention Registry on Venous Thromboembolism) Predictive score was developed to assess VTE risk in hospitalized medical patients and help identify patients who may not require pharmacological thromboprophylaxis. This validated clinical prediction tool uses 7 clinical variables present at admission or during hospitalization to stratify patients into risk categories. Patients with scores <2 (representing <1% 3-month VTE risk) may not warrant pharmacologic thromboprophylaxis, while those with scores ≥2 should receive prophylaxis. The score is particularly valuable for identifying low-risk medical patients who can safely avoid anticoagulation.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2013 Spyropoulos

    IMPROVE Bleeding Risk Score

    The IMPROVE Bleeding Risk Score is indicated for bedside clinical practice to support Assesses bleeding risk at hospital admission for acutely ill medical patients, particularly when considering anticoagulation therapy. The IMPROVE Bleeding Risk Score was developed from an international observational database of 15,156 patients across 52 hospitals in 12 countries to predict major bleeding and clinically relevant non-major bleeding within 14 days of admission. The cumulative incidence of major and non-major but clinically relevant in-hospital bleeding within 14 days of admission was 3.2%. This validated tool helps clinicians identify patients at high risk for bleeding complications and assess the risk-benefit ratio of pharmacological thromboprophylaxis. Patients with scores ≥7 have significantly greater rates of major bleeding (3.9% vs 1.2%) and should be carefully evaluated before anticoagulation.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2020

    VTE-BLEED Score

    The VTE-BLEED Score is indicated for bedside clinical practice to support Assesses bleeding risk on anticoagulation therapy in patients with venous thromboembolism (VTE). This validated risk score enables better stratification of bleeding risk during stable anticoagulation after a first VTE episode. Unlike bleeding risk scores derived from atrial fibrillation patients, the VTE-BLEED score is specifically designed for VTE patients who have different comorbidity profiles and risk factors.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology1998

    MASCC Risk Index for Febrile Neutropenia

    The MASCC Risk Index for Febrile Neutropenia is indicated for bedside clinical practice to support Identifies febrile neutropenia patients at low risk for poor outcome including death, intensive care unit admission, confusion, cardiac complications, respiratory failure, renal failure, hypotension, bleeding, and other serious medical complications. Developed by Multinational Association for Supportive Care in Cancer (MASCC) to guide outpatient vs inpatient management decisions.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2014

    HScore for Reactive Hemophagocytic Syndrome

    The HScore for Reactive Hemophagocytic Syndrome is indicated for bedside clinical practice to support Estimates the risk of having reactive hemophagocytic syndrome (RHS) based on clinical, laboratory, and histologic findings. Uses nine variables to provide a probability score ranging from <1% to >99% for RHS diagnosis.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2012

    DASH Prediction Score for Recurrent VTE

    The DASH Prediction Score for Recurrent VTE is indicated for bedside clinical practice to support Predicts likelihood of recurrence of first unprovoked venous thromboembolism (VTE) to guide anticoagulation duration decisions. Utilizes D-dimer, Age, Sex, and Hormonal therapy factors.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2008

    HERDOO2 Rule for Discontinuing Anticoagulation in Unprovoked VTE

    The HERDOO2 Rule for Discontinuing Anticoagulation in Unprovoked VTE is indicated for bedside clinical practice to support Identifies low-risk women who can safely discontinue anticoagulation after completing treatment for unprovoked venous thromboembolism (VTE). The rule helps clinicians decide which patients can stop anticoagulation therapy after the initial treatment period.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology1973

    Mentzer Index

    The Mentzer Index is indicated for bedside clinical practice to support Differentiates beta thalassemia trait from iron deficiency anemia using MCV and RBC count. A simple screening tool that helps distinguish between these two common causes of microcytic anemia.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology1962

    Blood Volume Calculation

    The Blood Volume Calculation is indicated for bedside clinical practice to support Calculates total blood volume, red blood cell volume, and plasma volume using Nadler equations based on age, sex, height, weight, and hematocrit. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2024

    Cryoprecipitate Dosing for Fibrinogen Replacement

    The Cryoprecipitate Dosing for Fibrinogen Replacement is indicated for bedside clinical practice to support Calculates the required dose of cryoprecipitate units needed to achieve target fibrinogen levels in patients with fibrinogen deficiency or hypofibrinogenemia. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology1983

    Maximum Allowable Blood Loss (ABL) Without Transfusion

    The Maximum Allowable Blood Loss (ABL) Without Transfusion is indicated for bedside clinical practice to support Estimates maximum allowable blood loss intraoperatively before transfusion should be considered. Essential for surgical blood loss management and transfusion decision-making based on patient weight, age group, initial hemoglobin, and acceptable final hemoglobin levels.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology1970

    Ganzoni Equation for Iron Deficiency Anemia

    The Ganzoni Equation for Iron Deficiency Anemia is indicated for bedside clinical practice to support Assesses total body iron deficit for iron replacement therapy. Calculates the precise amount of iron needed to replenish body iron stores and correct hemoglobin levels in patients with iron deficiency anemia.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2018

    Maternal-Fetal Hemorrhage Rh(D) Immune Globulin Dosage

    The Maternal-Fetal Hemorrhage Rh(D) Immune Globulin Dosage is indicated for bedside clinical practice to support Calculates amount of RhIG (RhoGAM) to be administered to Rh-negative mother following maternal-fetal hemorrhage to prevent hemolytic disease of the fetus and newborn (HDFN). Essential for preventing maternal anti-D antibody formation when Rh-negative mother is exposed to Rh-positive fetal blood.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2019 Sanfilippo

    IMPEDE-VTE

    The IMPEDE-VTE is indicated for bedside clinical practice to support Predicts risk of venous thromboembolism (VTE) in patients with multiple myeloma receiving treatment. The IMPEDE-VTE score was developed and validated in large cohorts (4,446 patients in derivation, 4,256 in validation) to identify multiple myeloma patients at highest risk for VTE during treatment. Patients with multiple myeloma have a 9-fold increased risk of VTE compared to the general population. This validated score helps clinicians identify patients who would benefit most from thromboprophylaxis and is incorporated into National Comprehensive Cancer Network (NCCN) guidelines. The model stratifies patients into low, intermediate, and high-risk categories with cumulative 6-month VTE incidences ranging from 3.8-5.0% (low risk) to 24.1-40.5% (high risk) across validation studies.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2001

    Neutrophil-Lymphocyte Ratio (NLR) Calculator

    The Neutrophil-Lymphocyte Ratio (NLR) Calculator is indicated for bedside clinical practice to support Calculates neutrophil-lymphocyte ratio. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2010

    HIT Expert Probability (HEP) Score for Heparin-Induced Thrombocytopenia

    The HIT Expert Probability (HEP) Score for Heparin-Induced Thrombocytopenia is indicated for bedside clinical practice to support Pre-test clinical scoring model for heparin-induced thrombocytopenia (HIT) based on broad expert opinion. Helps guide clinical decisions regarding therapy and reduces unnecessary use of alternative anticoagulants.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2011

    EUTOS Score for Chronic Myelogenous Leukemia (CML)

    The EUTOS Score for Chronic Myelogenous Leukemia (CML) is indicated for bedside clinical practice to support Predicts outcomes after CML treatments, specifically adjusted for tyrosine kinase inhibitor treatments. Predicts probability of complete cytogenetic response at 18 months and progression-free survival.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology1977

    Binet Staging System for Chronic Lymphocytic Leukemia (CLL)

    The Binet Staging System for Chronic Lymphocytic Leukemia (CLL) is indicated for bedside clinical practice to support Stages chronic lymphocytic leukemia based on lymphadenopathy areas and hematologic parameters to predict prognosis and guide treatment decisions. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2016

    International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI)

    The International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) is indicated for bedside clinical practice to support Stratifies chronic lymphocytic leukemia patients into four risk categories based on five independent prognostic factors. The CLL-IPI combines genetic (TP53 status, IGHV mutational status), biochemical (β2-microglobulin), and clinical parameters (age, clinical stage) to predict overall survival and treatment outcomes. This validated prognostic model discriminates four risk groups with significantly different 5-year overall survival rates: low risk (93.2%), intermediate risk (79.3%), high risk (63.3%), and very high risk (23.3%). The CLL-IPI enables more targeted patient management and risk-adapted treatment strategies in clinical practice and clinical trials.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2007

    International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI)

    The International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI) is indicated for bedside clinical practice to support Predicts overall and progression-free survival in diffuse large B-cell lymphoma (DLBCL) based on five independent risk factors. The original IPI (International Prognostic Index) was developed in the pre-rituximab era and identifies four risk groups based on age, performance status, disease stage, LDH level, and extranodal involvement. The R-IPI (Revised IPI) was developed for the rituximab era to better discriminate outcomes in patients receiving R-CHOP therapy, redistributing patients into three prognostic groups with improved clinical utility. Both indices provide valuable prognostic information for treatment planning, clinical trial stratification, and patient counseling in DLBCL management.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2004

    Follicular Lymphoma International Prognostic Index (FLIPI)

    The Follicular Lymphoma International Prognostic Index (FLIPI) is indicated for bedside clinical practice to support Estimates overall survival in patients with follicular lymphoma based on 5 adverse prognostic factors to stratify patients into risk groups for treatment planning.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2008

    Mantle Cell Lymphoma International Prognostic Index (MIPI)

    The Mantle Cell Lymphoma International Prognostic Index (MIPI) is indicated for bedside clinical practice to support Predicts survival in mantle cell lymphoma patients using age, performance status, lactate dehydrogenase level, and white blood cell count. More specific to mantle cell lymphoma than the International Prognostic Index (IPI). Stratifies patients into low, intermediate, and high risk categories for prognostic planning and treatment decisions.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2014

    National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI)

    The National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) is indicated for bedside clinical practice to support Predicts survival in patients with diffuse large B-cell lymphoma (DLBCL) using age, LDH levels, extranodal involvement, Ann Arbor stage, and ECOG performance status. Developed for the rituximab era with enhanced prognostic discrimination.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2016

    Central Nervous System International Prognostic Index (CNS-IPI)

    The Central Nervous System International Prognostic Index (CNS-IPI) is indicated for bedside clinical practice to support Prognostic scoring system that predicts the risk of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP chemotherapy. Helps identify patients who may benefit from CNS-directed prophylaxis and guides treatment planning decisions.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2005

    Multiple Myeloma International Staging System (ISS)

    The Multiple Myeloma International Staging System (ISS) is indicated for bedside clinical practice to support Prognosticates severity of multiple myeloma based on routinely obtained lab values including serum β2 microglobulin and albumin levels.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2014

    Multiple Myeloma Diagnostic Criteria (IMWG)

    The Multiple Myeloma Diagnostic Criteria (IMWG) is indicated for bedside clinical practice to support Diagnoses multiple myeloma according to the International Myeloma Working Group (IMWG) criteria, including traditional CRAB criteria and newer SLiM biomarkers.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2016

    Multiple Myeloma Response Criteria (IMWG)

    The Multiple Myeloma Response Criteria (IMWG) is indicated for bedside clinical practice to support Evaluates disease response in multiple myeloma according to International Myeloma Working Group (IMWG) criteria including Complete Response, Partial Response, and Progressive Disease categories.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2016

    WHO Diagnostic Criteria for Polycythemia Vera (2016)

    The WHO Diagnostic Criteria for Polycythemia Vera (2016) is indicated for bedside clinical practice to support World Health Organization 2016 diagnostic criteria for polycythemia vera. Requires 3 major criteria OR 2 major criteria + 1 minor criterion for diagnosis. Designed to detect masked polycythemia vera cases missed by previous 2008 criteria.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2011

    DIPSS/DIPSS Plus (Dynamic International Prognostic Scoring System) for Myelofibrosis

    The DIPSS/DIPSS Plus (Dynamic International Prognostic Scoring System) for Myelofibrosis is indicated for bedside clinical practice to support Estimates survival in patients with primary myelofibrosis using clinical and laboratory parameters. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2018

    GIPSS - Genetically Inspired Prognostic Scoring System for Primary Myelofibrosis

    The GIPSS - Genetically Inspired Prognostic Scoring System for Primary Myelofibrosis is indicated for bedside clinical practice to support The GIPSS is a genetically-based prognostic scoring system for primary myelofibrosis that relies exclusively on cytogenetic and molecular genetic markers. This system eliminates subjective clinical variables and provides more accurate risk stratification for treatment planning, particularly for allogeneic stem cell transplant decisions.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2018

    Mutation-Enhanced International Prognostic Score System (MIPSS70/MIPSS70+)

    The Mutation-Enhanced International Prognostic Score System (MIPSS70/MIPSS70+) is indicated for bedside clinical practice to support Stratifies risk for patients with overt primary myelofibrosis (PMF) using clinical, laboratory, and molecular genetic parameters. This enhanced prognostic system incorporates high molecular risk mutations to improve risk stratification beyond traditional clinical factors.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2017

    Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSEC-PM)

    The Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSEC-PM) is indicated for bedside clinical practice to support Predicts survival in patients with myelofibrosis secondary to polycythemia vera (PV) and essential thrombocythemia (ET). This specialized prognostic model was developed specifically for secondary myelofibrosis, incorporating clinical parameters and molecular genetic information to provide superior risk stratification compared to models designed for primary myelofibrosis.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2017

    Michigan Risk Score for PICC-Related Thrombosis

    The Michigan Risk Score for PICC-Related Thrombosis is indicated for bedside clinical practice to support Predicts risk of deep vein thrombosis (DVT) in patients with peripherally inserted central catheter (PICC). It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2005, Age-adjusted 2014

    Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI)

    The Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) is indicated for bedside clinical practice to support Predicts survival after HCT in patients with hematologic malignancies, including optional age adjustment. The HCT-CI comprises 17 different categories of organ dysfunction and has been validated as more sensitive than the Charlson Comorbidity Index for HCT patients.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2010

    Duval/CIBMTR Score for Acute Myelogenous Leukemia (AML) Survival

    The Duval/CIBMTR Score for Acute Myelogenous Leukemia (AML) Survival is indicated for bedside clinical practice to support Predicts transplantation survival of AML patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) based on five pre-transplant risk factors.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2022

    International Consensus Classification (ICC) Diagnostic Criteria for Primary Myelofibrosis (PMF)

    The International Consensus Classification (ICC) Diagnostic Criteria for Primary Myelofibrosis (PMF) is indicated for bedside clinical practice to support Diagnoses primary myelofibrosis according to the International Consensus Classification (ICC) criteria published in 2022. This systematic diagnostic framework distinguishes between prefibrotic (early) and overt (fibrotic) stages of primary myelofibrosis using morphological, genetic, and clinical criteria. The ICC criteria refine the WHO classification system by providing better diagnostic specificity for myeloproliferative neoplasms. The diagnosis requires all three major criteria plus at least one minor criterion, confirmed in two consecutive determinations. This classification facilitates accurate diagnosis, appropriate staging, prognostic assessment, and treatment planning for patients with suspected primary myelofibrosis. The tool is particularly valuable for hematologists and pathologists in differentiating PMF from other myeloproliferative neoplasms and establishing precise diagnostic categorization.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2022

    International Consensus Classification (ICC) Diagnostic Criteria for Systemic Mastocytosis

    The International Consensus Classification (ICC) Diagnostic Criteria for Systemic Mastocytosis is indicated for bedside clinical practice to support Diagnoses systemic mastocytosis according to the International Consensus Classification (ICC) criteria using morphological, immunophenotypic, and molecular parameters. The ICC criteria refine the WHO classification system with enhanced diagnostic specificity for mast cell disorders.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2018

    Mayo Alliance Prognostic System (MAPS) Score

    The Mayo Alliance Prognostic System (MAPS) Score is indicated for bedside clinical practice to support Assesses prognosis of systemic mastocytosis using clinical and molecular risk factors. Developed at Mayo Clinic to provide contemporary risk stratification for patients with systemic mastocytosis, incorporating both clinical parameters and molecular genetic information for accurate survival prediction.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2016

    WHO Diagnostic Criteria for Systemic Mastocytosis (2016)

    The WHO Diagnostic Criteria for Systemic Mastocytosis (2016) is indicated for bedside clinical practice to support World Health Organization 2016 diagnostic criteria for systemic mastocytosis. Requires 1 major criterion + 1 minor criterion OR 3 minor criteria for diagnosis. Used to distinguish systemic mastocytosis from cutaneous mastocytosis and other mast cell disorders.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • HematologyMalcovati 2007

    WPSS (WHO classification-based Prognostic Scoring System) for Myelodysplastic Syndrome

    The WPSS (WHO classification-based Prognostic Scoring System) for Myelodysplastic Syndrome is indicated for bedside clinical practice to support Assesses prognosis of patients with myelodysplastic syndrome (MDS) based on WHO morphological classification, cytogenetics, and transfusion requirement. The WPSS provides dynamic prognostic assessment throughout disease course and stratifies patients into five risk groups.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology1997

    Groupe d'Etude des Lymphomes Folliculaires (GELF) Criteria

    The Groupe d'Etude des Lymphomes Folliculaires (GELF) Criteria is indicated for bedside clinical practice to support Determines if immediate therapy for follicular lymphoma is needed by identifying high tumor burden patients requiring treatment rather than active surveillance. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2017

    MALT Lymphoma Prognostic Index (MALT-IPI)

    The MALT Lymphoma Prognostic Index (MALT-IPI) is indicated for bedside clinical practice to support Identifies MALT lymphoma patients at risk for poor outcomes using three clinical parameters: age ≥70 years, Ann Arbor stage III/IV, and elevated lactate dehydrogenase (LDH). Stratifies patients into low, intermediate, and high risk groups predictive for event-free survival and overall survival.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2020

    International Prognostic Score for Asymptomatic Early-stage CLL (IPS-E)

    The International Prognostic Score for Asymptomatic Early-stage CLL (IPS-E) is indicated for bedside clinical practice to support Assesses prognosis of asymptomatic early-stage chronic lymphocytic leukemia (CLL) to predict time to first treatment (TTFT). The IPS-E was developed using individual patient data from 11 international cohorts (n=4933) and uses three independent prognostic factors to stratify patients into low, intermediate, and high-risk categories. This scoring system specifically addresses the clinical need for prognostic stratification in early-stage asymptomatic CLL patients who do not require immediate treatment according to iwCLL criteria. The IPS-E demonstrates excellent discrimination with C-index values of 0.74 in training and 0.70 in validation cohorts, making it a valuable tool for clinical management and early intervention clinical trial design. It enables clinicians to identify patients who may benefit from closer monitoring or consideration for clinical trials.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2019

    BALL Score for Relapsed/Refractory CLL

    The BALL Score for Relapsed/Refractory CLL is indicated for bedside clinical practice to support Assesses prognosis of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) on targeted therapies. The BALL Score (β2-microglobulin, Anemia, LDH, Last Therapy) helps estimate survival outcomes in patients with R/R-CLL who require further treatment with targeted therapies.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2006

    HEMORR₂HAGES Score for Major Bleeding Risk

    The HEMORR₂HAGES Score for Major Bleeding Risk is indicated for bedside clinical practice to support Quantifies hemorrhage risk in elderly patients with atrial fibrillation on anticoagulation therapy. The score helps clinicians assess bleeding risk when considering anticoagulation for stroke prevention in AF patients.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2010

    ISTH-SCC Bleeding Assessment Tool

    The ISTH-SCC Bleeding Assessment Tool is indicated for bedside clinical practice to support Assesses bleeding symptoms in patients with inherited bleeding disorders. This standardized questionnaire was developed by the International Society on Thrombosis and Haemostasis (ISTH) Scientific and Standardization Committee (SSC) to evaluate 14 different bleeding symptoms and identify patients who may have inherited bleeding disorders requiring further investigation.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2010

    Donor Lymphocyte Infusion (DLI) Volume

    The Donor Lymphocyte Infusion (DLI) Volume is indicated for bedside clinical practice to support Estimates total blood volume to process by apheresis to produce appropriate DLI dosage. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • HematologyVillalta 1994

    Villalta Score for Post-thrombotic Syndrome (PTS)

    The Villalta Score for Post-thrombotic Syndrome (PTS) is indicated for bedside clinical practice to support Diagnoses and stratifies severity of post-thrombotic syndrome in patients with history of deep venous thrombosis (DVT). The score combines patient-reported symptoms with physician-assessed clinical signs to provide standardized PTS evaluation.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2006

    Geneva Risk Score for Venous Thromboembolism (VTE) Prophylaxis

    The Geneva Risk Score for Venous Thromboembolism (VTE) Prophylaxis is indicated for bedside clinical practice to support Predicts the need for venous thromboembolism (VTE) prophylaxis in hospitalized medical patients by assessing risk factors to identify patients who would benefit from thromboprophylaxis versus those at low risk who may not require anticoagulation. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2017 Gibson

    IMPROVEDD Risk Score for Venous Thromboembolism (VTE)

    The IMPROVEDD Risk Score for Venous Thromboembolism (VTE) is indicated for bedside clinical practice to support Predicts 77-day risk of acute venous thromboembolism (VTE) in hospitalized medical patients by incorporating D-dimer levels into the IMPROVE Risk Score. The IMPROVEDD (IMPROVE + D-dimer) score enhances the original IMPROVE VTE risk assessment by adding D-dimer ≥2× upper limit of normal as an additional risk factor worth 2 points. This validated clinical prediction tool was developed from the APEX trial involving 7,441 hospitalized medically ill patients. The addition of D-dimer significantly improves VTE risk discrimination and reclassification compared to the original IMPROVE score. An IMPROVEDD score ≥2 identifies patients with heightened VTE risk through 77 days, helping clinicians make more informed decisions about extended thromboprophylaxis duration in acutely ill medical patients.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2009

    ABC Score for Massive Transfusion

    The ABC Score for Massive Transfusion is indicated for bedside clinical practice to support Predicts the necessity for massive transfusion in trauma patients using clinical variables available at initial assessment. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematologystandard

    Absolute Eosinophil Count

    The Absolute Eosinophil Count is indicated for bedside clinical practice to support Absolute eosinophil count from WBC and differential.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology1998

    Absolute Lymphocyte Count (ALC)

    The Absolute Lymphocyte Count (ALC) is indicated for bedside clinical practice to support Assesses lymphocyte count and predicts CD4 count in HIV patients. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematologystandard

    Absolute Reticulocyte Count

    The Absolute Reticulocyte Count is indicated for bedside clinical practice to support Absolute reticulocyte count for anemia workup.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2013

    Adjusted Gapss Antiphospholipid Syndrome Risk

    The Adjusted Gapss Antiphospholipid Syndrome Risk is indicated for bedside clinical practice to support Adjusted GAPSS: thrombotic risk in antiphospholipid syndrome.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology1981

    Binet Stage for Chronic Lymphocytic Leukaemia

    The Binet Stage for Chronic Lymphocytic Leukaemia is indicated for bedside clinical practice to support Binet staging for chronic lymphocytic leukemia.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2021

    CAR-HEMATOTOX Score

    The CAR-HEMATOTOX Score is indicated for bedside clinical practice to support Pre-lymphodepletion risk stratification for prolonged hematologic toxicity and severe infections after CAR-T therapy.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology1.0

    Corrected Reticulocyte Count

    The Corrected Reticulocyte Count is indicated for bedside clinical practice to support Reticulocyte percentage corrected for anemia.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2022

    ELN 2022 AML Risk Stratification

    The ELN 2022 AML Risk Stratification is indicated for bedside clinical practice to support ELN 2022 genetic risk classification for acute myeloid leukemia.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology1968

    Ganzoni Iron Deficit

    The Ganzoni Iron Deficit is indicated for bedside clinical practice to support Calculates total body iron deficit to guide parenteral iron replacement dosing.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2001

    ISTH Overt DIC Score

    The ISTH Overt DIC Score is indicated for bedside clinical practice to support Diagnoses overt disseminated intravascular coagulation in patients with an underlying compatible condition.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2006

    JAAM DIC Score

    The JAAM DIC Score is indicated for bedside clinical practice to support Japanese Association for Acute Medicine DIC score for early diagnosis in critical care.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2008

    Khorana Score (Chemotherapy-Associated VTE Risk)

    The Khorana Score (Chemotherapy-Associated VTE Risk) is indicated for bedside clinical practice to support Predicts risk of venous thromboembolism in ambulatory cancer patients starting chemotherapy.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2017

    PLASMIC Score — TTP Risk Stratification

    The PLASMIC Score — TTP Risk Stratification is indicated for bedside clinical practice to support The PLASMIC score predicts severe ADAMTS13 deficiency in suspected thrombotic thrombocytopenic purpura. 7 items, 1 point each. Total 0-7.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology

    Platelet-to-Lymphocyte Ratio (PLR)

    The Platelet-to-Lymphocyte Ratio (PLR) is indicated for bedside clinical practice to support PLR is a systemic inflammation marker: platelets divided by lymphocytes (same units). Reported as a continuous value; no single validated cutoff.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2013

    Polycythemia Vera Thrombosis Risk

    The Polycythemia Vera Thrombosis Risk is indicated for bedside clinical practice to support ELN/Tefferi risk stratification for thrombosis in polycythemia vera: high risk if age >= 60 or prior thrombosis.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2012

    Revised International Prognostic Scoring System (IPSS-R) for MDS

    The Revised International Prognostic Scoring System (IPSS-R) for MDS is indicated for bedside clinical practice to support Prognostic scoring for myelodysplastic syndromes: cytogenetics, blasts, hemoglobin, platelets, ANC.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2015

    Revised International Staging System (R-ISS) for Multiple Myeloma

    The Revised International Staging System (R-ISS) for Multiple Myeloma is indicated for bedside clinical practice to support Myeloma staging combining ISS, LDH and high-risk cytogenetics.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology1984

    Sokal Score (CML Prognosis)

    The Sokal Score (CML Prognosis) is indicated for bedside clinical practice to support CML prognostic score at diagnosis: <0.8 low, 0.8-1.2 intermediate, >1.2 high risk.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology

    Soluble Transferrin Receptor / Ferritin Index

    The Soluble Transferrin Receptor / Ferritin Index is indicated for bedside clinical practice to support sTfR/log(ferritin) index helps distinguish iron deficiency from anemia of chronic disease.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology1962

    Total Blood Volume (Nadler)

    The Total Blood Volume (Nadler) is indicated for bedside clinical practice to support Estimates total blood volume (BV) in adults using the Nadler formula (1962): sex-specific equations from height (m) and weight (kg). Result in liters; multiply by 1000 for mL.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematologystandard

    Transferrin Saturation

    The Transferrin Saturation is indicated for bedside clinical practice to support Transferrin saturation for iron deficiency evaluation.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology1993

    Weight-Based Heparin Dosing (Raschke)

    The Weight-Based Heparin Dosing (Raschke) is indicated for bedside clinical practice to support Weight-based unfractionated heparin bolus and infusion per the Raschke nomogram, with absolute maximum caps.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2006

    4Ts Score for Heparin-Induced Thrombocytopenia

    The 4Ts Score for Heparin-Induced Thrombocytopenia is indicated for bedside clinical practice to support Differentiates patients with heparin-induced thrombocytopenia (HIT) from those with other causes of thrombocytopenia. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2009

    ABC Score for Massive Transfusion

    The ABC Score for Massive Transfusion is indicated for bedside clinical practice to support Predicts the necessity for massive transfusion in trauma patients using clinical variables available at initial assessment. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematologystandard

    Absolute Eosinophil Count

    The Absolute Eosinophil Count is indicated for bedside clinical practice to support Absolute eosinophil count from WBC and differential.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematologystandard

    Absolute Reticulocyte Count

    The Absolute Reticulocyte Count is indicated for bedside clinical practice to support Absolute reticulocyte count for anemia workup.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2013

    Adjusted Gapss Antiphospholipid Syndrome Risk

    The Adjusted Gapss Antiphospholipid Syndrome Risk is indicated for bedside clinical practice to support Adjusted GAPSS: thrombotic risk in antiphospholipid syndrome.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2019

    BALL Score for Relapsed/Refractory CLL

    The BALL Score for Relapsed/Refractory CLL is indicated for bedside clinical practice to support Assesses prognosis of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) on targeted therapies. The BALL Score (β2-microglobulin, Anemia, LDH, Last Therapy) helps estimate survival outcomes in patients with R/R-CLL who require further treatment with targeted therapies.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology1981

    Binet Stage for Chronic Lymphocytic Leukaemia

    The Binet Stage for Chronic Lymphocytic Leukaemia is indicated for bedside clinical practice to support Binet staging for chronic lymphocytic leukemia.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology1977

    Binet Staging System for Chronic Lymphocytic Leukemia (CLL)

    The Binet Staging System for Chronic Lymphocytic Leukemia (CLL) is indicated for bedside clinical practice to support Stages chronic lymphocytic leukemia based on lymphadenopathy areas and hematologic parameters to predict prognosis and guide treatment decisions. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology1962

    Blood Volume Calculation

    The Blood Volume Calculation is indicated for bedside clinical practice to support Calculates total blood volume, red blood cell volume, and plasma volume using Nadler equations based on age, sex, height, weight, and hematocrit. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2016

    International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI)

    The International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) is indicated for bedside clinical practice to support Stratifies chronic lymphocytic leukemia patients into four risk categories based on five independent prognostic factors. The CLL-IPI combines genetic (TP53 status, IGHV mutational status), biochemical (β2-microglobulin), and clinical parameters (age, clinical stage) to predict overall survival and treatment outcomes. This validated prognostic model discriminates four risk groups with significantly different 5-year overall survival rates: low risk (93.2%), intermediate risk (79.3%), high risk (63.3%), and very high risk (23.3%). The CLL-IPI enables more targeted patient management and risk-adapted treatment strategies in clinical practice and clinical trials.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2016

    Central Nervous System International Prognostic Index (CNS-IPI)

    The Central Nervous System International Prognostic Index (CNS-IPI) is indicated for bedside clinical practice to support Prognostic scoring system that predicts the risk of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP chemotherapy. Helps identify patients who may benefit from CNS-directed prophylaxis and guides treatment planning decisions.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2021

    Corrected Count Increment (CCI) for Platelet Transfusion

    The Corrected Count Increment (CCI) for Platelet Transfusion is indicated for bedside clinical practice to support Assesses adequacy of response to platelet transfusion by measuring the expected increase in platelets adjusted for patient size and platelet dose. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology1.0

    Corrected Reticulocyte Count

    The Corrected Reticulocyte Count is indicated for bedside clinical practice to support Reticulocyte percentage corrected for anemia.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2024

    Cryoprecipitate Dosing for Fibrinogen Replacement

    The Cryoprecipitate Dosing for Fibrinogen Replacement is indicated for bedside clinical practice to support Calculates the required dose of cryoprecipitate units needed to achieve target fibrinogen levels in patients with fibrinogen deficiency or hypofibrinogenemia. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2012

    DASH Prediction Score for Recurrent VTE

    The DASH Prediction Score for Recurrent VTE is indicated for bedside clinical practice to support Predicts likelihood of recurrence of first unprovoked venous thromboembolism (VTE) to guide anticoagulation duration decisions. Utilizes D-dimer, Age, Sex, and Hormonal therapy factors.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2011

    DIPSS/DIPSS Plus (Dynamic International Prognostic Scoring System) for Myelofibrosis

    The DIPSS/DIPSS Plus (Dynamic International Prognostic Scoring System) for Myelofibrosis is indicated for bedside clinical practice to support Estimates survival in patients with primary myelofibrosis using clinical and laboratory parameters. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2007

    International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI)

    The International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI) is indicated for bedside clinical practice to support Predicts overall and progression-free survival in diffuse large B-cell lymphoma (DLBCL) based on five independent risk factors. The original IPI (International Prognostic Index) was developed in the pre-rituximab era and identifies four risk groups based on age, performance status, disease stage, LDH level, and extranodal involvement. The R-IPI (Revised IPI) was developed for the rituximab era to better discriminate outcomes in patients receiving R-CHOP therapy, redistributing patients into three prognostic groups with improved clinical utility. Both indices provide valuable prognostic information for treatment planning, clinical trial stratification, and patient counseling in DLBCL management.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2010

    Donor Lymphocyte Infusion (DLI) Volume

    The Donor Lymphocyte Infusion (DLI) Volume is indicated for bedside clinical practice to support Estimates total blood volume to process by apheresis to produce appropriate DLI dosage. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2010

    Duval/CIBMTR Score for Acute Myelogenous Leukemia (AML) Survival

    The Duval/CIBMTR Score for Acute Myelogenous Leukemia (AML) Survival is indicated for bedside clinical practice to support Predicts transplantation survival of AML patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) based on five pre-transplant risk factors.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2022

    ELN 2022 AML Risk Stratification

    The ELN 2022 AML Risk Stratification is indicated for bedside clinical practice to support ELN 2022 genetic risk classification for acute myeloid leukemia.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2011

    EUTOS Score for Chronic Myelogenous Leukemia (CML)

    The EUTOS Score for Chronic Myelogenous Leukemia (CML) is indicated for bedside clinical practice to support Predicts outcomes after CML treatments, specifically adjusted for tyrosine kinase inhibitor treatments. Predicts probability of complete cytogenetic response at 18 months and progression-free survival.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology1970

    Ganzoni Equation for Iron Deficiency Anemia

    The Ganzoni Equation for Iron Deficiency Anemia is indicated for bedside clinical practice to support Assesses total body iron deficit for iron replacement therapy. Calculates the precise amount of iron needed to replenish body iron stores and correct hemoglobin levels in patients with iron deficiency anemia.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology1968

    Ganzoni Iron Deficit

    The Ganzoni Iron Deficit is indicated for bedside clinical practice to support Calculates total body iron deficit to guide parenteral iron replacement dosing.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology1997

    Groupe d'Etude des Lymphomes Folliculaires (GELF) Criteria

    The Groupe d'Etude des Lymphomes Folliculaires (GELF) Criteria is indicated for bedside clinical practice to support Determines if immediate therapy for follicular lymphoma is needed by identifying high tumor burden patients requiring treatment rather than active surveillance. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2006

    Geneva Risk Score for Venous Thromboembolism (VTE) Prophylaxis

    The Geneva Risk Score for Venous Thromboembolism (VTE) Prophylaxis is indicated for bedside clinical practice to support Predicts the need for venous thromboembolism (VTE) prophylaxis in hospitalized medical patients by assessing risk factors to identify patients who would benefit from thromboprophylaxis versus those at low risk who may not require anticoagulation. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2018

    GIPSS - Genetically Inspired Prognostic Scoring System for Primary Myelofibrosis

    The GIPSS - Genetically Inspired Prognostic Scoring System for Primary Myelofibrosis is indicated for bedside clinical practice to support The GIPSS is a genetically-based prognostic scoring system for primary myelofibrosis that relies exclusively on cytogenetic and molecular genetic markers. This system eliminates subjective clinical variables and provides more accurate risk stratification for treatment planning, particularly for allogeneic stem cell transplant decisions.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2010

    HAS-BLED Score for Major Bleeding Risk

    The HAS-BLED Score for Major Bleeding Risk is indicated for bedside clinical practice to support Estimates 1-year risk of major bleeding for patients on anticoagulation to assess quality of atrial fibrillation care. Used with CHA2DS2-VASc score to balance stroke vs bleeding risk.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2005, Age-adjusted 2014

    Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI)

    The Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) is indicated for bedside clinical practice to support Predicts survival after HCT in patients with hematologic malignancies, including optional age adjustment. The HCT-CI comprises 17 different categories of organ dysfunction and has been validated as more sensitive than the Charlson Comorbidity Index for HCT patients.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2021

    CAR-HEMATOTOX Score

    The CAR-HEMATOTOX Score is indicated for bedside clinical practice to support Pre-lymphodepletion risk stratification for prolonged hematologic toxicity and severe infections after CAR-T therapy.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2010

    HIT Expert Probability (HEP) Score for Heparin-Induced Thrombocytopenia

    The HIT Expert Probability (HEP) Score for Heparin-Induced Thrombocytopenia is indicated for bedside clinical practice to support Pre-test clinical scoring model for heparin-induced thrombocytopenia (HIT) based on broad expert opinion. Helps guide clinical decisions regarding therapy and reduces unnecessary use of alternative anticoagulants.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology1993

    Weight-Based Heparin Dosing (Raschke)

    The Weight-Based Heparin Dosing (Raschke) is indicated for bedside clinical practice to support Weight-based unfractionated heparin bolus and infusion per the Raschke nomogram, with absolute maximum caps.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2022

    International Consensus Classification (ICC) Diagnostic Criteria for Primary Myelofibrosis (PMF)

    The International Consensus Classification (ICC) Diagnostic Criteria for Primary Myelofibrosis (PMF) is indicated for bedside clinical practice to support Diagnoses primary myelofibrosis according to the International Consensus Classification (ICC) criteria published in 2022. This systematic diagnostic framework distinguishes between prefibrotic (early) and overt (fibrotic) stages of primary myelofibrosis using morphological, genetic, and clinical criteria. The ICC criteria refine the WHO classification system by providing better diagnostic specificity for myeloproliferative neoplasms. The diagnosis requires all three major criteria plus at least one minor criterion, confirmed in two consecutive determinations. This classification facilitates accurate diagnosis, appropriate staging, prognostic assessment, and treatment planning for patients with suspected primary myelofibrosis. The tool is particularly valuable for hematologists and pathologists in differentiating PMF from other myeloproliferative neoplasms and establishing precise diagnostic categorization.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2022

    International Consensus Classification (ICC) Diagnostic Criteria for Systemic Mastocytosis

    The International Consensus Classification (ICC) Diagnostic Criteria for Systemic Mastocytosis is indicated for bedside clinical practice to support Diagnoses systemic mastocytosis according to the International Consensus Classification (ICC) criteria using morphological, immunophenotypic, and molecular parameters. The ICC criteria refine the WHO classification system with enhanced diagnostic specificity for mast cell disorders.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2019 Sanfilippo

    IMPEDE-VTE

    The IMPEDE-VTE is indicated for bedside clinical practice to support Predicts risk of venous thromboembolism (VTE) in patients with multiple myeloma receiving treatment. The IMPEDE-VTE score was developed and validated in large cohorts (4,446 patients in derivation, 4,256 in validation) to identify multiple myeloma patients at highest risk for VTE during treatment. Patients with multiple myeloma have a 9-fold increased risk of VTE compared to the general population. This validated score helps clinicians identify patients who would benefit most from thromboprophylaxis and is incorporated into National Comprehensive Cancer Network (NCCN) guidelines. The model stratifies patients into low, intermediate, and high-risk categories with cumulative 6-month VTE incidences ranging from 3.8-5.0% (low risk) to 24.1-40.5% (high risk) across validation studies.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2013 Spyropoulos

    IMPROVE Bleeding Risk Score

    The IMPROVE Bleeding Risk Score is indicated for bedside clinical practice to support Assesses bleeding risk at hospital admission for acutely ill medical patients, particularly when considering anticoagulation therapy. The IMPROVE Bleeding Risk Score was developed from an international observational database of 15,156 patients across 52 hospitals in 12 countries to predict major bleeding and clinically relevant non-major bleeding within 14 days of admission. The cumulative incidence of major and non-major but clinically relevant in-hospital bleeding within 14 days of admission was 3.2%. This validated tool helps clinicians identify patients at high risk for bleeding complications and assess the risk-benefit ratio of pharmacological thromboprophylaxis. Patients with scores ≥7 have significantly greater rates of major bleeding (3.9% vs 1.2%) and should be carefully evaluated before anticoagulation.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2011 Spyropoulos

    IMPROVE Risk Score for Venous Thromboembolism (VTE)

    The IMPROVE Risk Score for Venous Thromboembolism (VTE) is indicated for bedside clinical practice to support Predicts 3-month risk of acute venous thromboembolism (VTE) in hospitalized medical patients. The IMPROVE (International Medical Prevention Registry on Venous Thromboembolism) Predictive score was developed to assess VTE risk in hospitalized medical patients and help identify patients who may not require pharmacological thromboprophylaxis. This validated clinical prediction tool uses 7 clinical variables present at admission or during hospitalization to stratify patients into risk categories. Patients with scores <2 (representing <1% 3-month VTE risk) may not warrant pharmacologic thromboprophylaxis, while those with scores ≥2 should receive prophylaxis. The score is particularly valuable for identifying low-risk medical patients who can safely avoid anticoagulation.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2017 Gibson

    IMPROVEDD Risk Score for Venous Thromboembolism (VTE)

    The IMPROVEDD Risk Score for Venous Thromboembolism (VTE) is indicated for bedside clinical practice to support Predicts 77-day risk of acute venous thromboembolism (VTE) in hospitalized medical patients by incorporating D-dimer levels into the IMPROVE Risk Score. The IMPROVEDD (IMPROVE + D-dimer) score enhances the original IMPROVE VTE risk assessment by adding D-dimer ≥2× upper limit of normal as an additional risk factor worth 2 points. This validated clinical prediction tool was developed from the APEX trial involving 7,441 hospitalized medically ill patients. The addition of D-dimer significantly improves VTE risk discrimination and reclassification compared to the original IMPROVE score. An IMPROVEDD score ≥2 identifies patients with heightened VTE risk through 77 days, helping clinicians make more informed decisions about extended thromboprophylaxis duration in acutely ill medical patients.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2020

    International Prognostic Score for Asymptomatic Early-stage CLL (IPS-E)

    The International Prognostic Score for Asymptomatic Early-stage CLL (IPS-E) is indicated for bedside clinical practice to support Assesses prognosis of asymptomatic early-stage chronic lymphocytic leukemia (CLL) to predict time to first treatment (TTFT). The IPS-E was developed using individual patient data from 11 international cohorts (n=4933) and uses three independent prognostic factors to stratify patients into low, intermediate, and high-risk categories. This scoring system specifically addresses the clinical need for prognostic stratification in early-stage asymptomatic CLL patients who do not require immediate treatment according to iwCLL criteria. The IPS-E demonstrates excellent discrimination with C-index values of 0.74 in training and 0.70 in validation cohorts, making it a valuable tool for clinical management and early intervention clinical trial design. It enables clinicians to identify patients who may benefit from closer monitoring or consideration for clinical trials.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2012

    Revised International Prognostic Scoring System (IPSS-R) for MDS

    The Revised International Prognostic Scoring System (IPSS-R) for MDS is indicated for bedside clinical practice to support Prognostic scoring for myelodysplastic syndromes: cytogenetics, blasts, hemoglobin, platelets, ANC.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2001

    ISTH Criteria for Disseminated Intravascular Coagulation (DIC)

    The ISTH Criteria for Disseminated Intravascular Coagulation (DIC) is indicated for bedside clinical practice to support Diagnoses overt disseminated intravascular coagulation (DIC) based on laboratory parameters. This scoring system was developed by the International Society on Thrombosis and Haemostasis (ISTH) as a standardized approach to DIC diagnosis using readily available laboratory tests. Use only in patients with clinical suspicion for DIC in appropriate clinical settings.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2001

    ISTH Overt DIC Score

    The ISTH Overt DIC Score is indicated for bedside clinical practice to support Diagnoses overt disseminated intravascular coagulation in patients with an underlying compatible condition.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2010

    ISTH-SCC Bleeding Assessment Tool

    The ISTH-SCC Bleeding Assessment Tool is indicated for bedside clinical practice to support Assesses bleeding symptoms in patients with inherited bleeding disorders. This standardized questionnaire was developed by the International Society on Thrombosis and Haemostasis (ISTH) Scientific and Standardization Committee (SSC) to evaluate 14 different bleeding symptoms and identify patients who may have inherited bleeding disorders requiring further investigation.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2006

    JAAM DIC Score

    The JAAM DIC Score is indicated for bedside clinical practice to support Japanese Association for Acute Medicine DIC score for early diagnosis in critical care.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2008

    Khorana Score (Chemotherapy-Associated VTE Risk)

    The Khorana Score (Chemotherapy-Associated VTE Risk) is indicated for bedside clinical practice to support Predicts risk of venous thromboembolism in ambulatory cancer patients starting chemotherapy.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2017

    MALT Lymphoma Prognostic Index (MALT-IPI)

    The MALT Lymphoma Prognostic Index (MALT-IPI) is indicated for bedside clinical practice to support Identifies MALT lymphoma patients at risk for poor outcomes using three clinical parameters: age ≥70 years, Ann Arbor stage III/IV, and elevated lactate dehydrogenase (LDH). Stratifies patients into low, intermediate, and high risk groups predictive for event-free survival and overall survival.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2008

    Mantle Cell Lymphoma International Prognostic Index (MIPI)

    The Mantle Cell Lymphoma International Prognostic Index (MIPI) is indicated for bedside clinical practice to support Predicts survival in mantle cell lymphoma patients using age, performance status, lactate dehydrogenase level, and white blood cell count. More specific to mantle cell lymphoma than the International Prognostic Index (IPI). Stratifies patients into low, intermediate, and high risk categories for prognostic planning and treatment decisions.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology1998

    MASCC Risk Index for Febrile Neutropenia

    The MASCC Risk Index for Febrile Neutropenia is indicated for bedside clinical practice to support Identifies febrile neutropenia patients at low risk for poor outcome including death, intensive care unit admission, confusion, cardiac complications, respiratory failure, renal failure, hypotension, bleeding, and other serious medical complications. Developed by Multinational Association for Supportive Care in Cancer (MASCC) to guide outpatient vs inpatient management decisions.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2018

    Maternal-Fetal Hemorrhage Rh(D) Immune Globulin Dosage

    The Maternal-Fetal Hemorrhage Rh(D) Immune Globulin Dosage is indicated for bedside clinical practice to support Calculates amount of RhIG (RhoGAM) to be administered to Rh-negative mother following maternal-fetal hemorrhage to prevent hemolytic disease of the fetus and newborn (HDFN). Essential for preventing maternal anti-D antibody formation when Rh-negative mother is exposed to Rh-positive fetal blood.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology1983

    Maximum Allowable Blood Loss (ABL) Without Transfusion

    The Maximum Allowable Blood Loss (ABL) Without Transfusion is indicated for bedside clinical practice to support Estimates maximum allowable blood loss intraoperatively before transfusion should be considered. Essential for surgical blood loss management and transfusion decision-making based on patient weight, age group, initial hemoglobin, and acceptable final hemoglobin levels.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2018

    Mayo Alliance Prognostic System (MAPS) Score

    The Mayo Alliance Prognostic System (MAPS) Score is indicated for bedside clinical practice to support Assesses prognosis of systemic mastocytosis using clinical and molecular risk factors. Developed at Mayo Clinic to provide contemporary risk stratification for patients with systemic mastocytosis, incorporating both clinical parameters and molecular genetic information for accurate survival prediction.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology1973

    Mentzer Index

    The Mentzer Index is indicated for bedside clinical practice to support Differentiates beta thalassemia trait from iron deficiency anemia using MCV and RBC count. A simple screening tool that helps distinguish between these two common causes of microcytic anemia.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2017

    Michigan Risk Score for PICC-Related Thrombosis

    The Michigan Risk Score for PICC-Related Thrombosis is indicated for bedside clinical practice to support Predicts risk of deep vein thrombosis (DVT) in patients with peripherally inserted central catheter (PICC). It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2014

    Multiple Myeloma Diagnostic Criteria (IMWG)

    The Multiple Myeloma Diagnostic Criteria (IMWG) is indicated for bedside clinical practice to support Diagnoses multiple myeloma according to the International Myeloma Working Group (IMWG) criteria, including traditional CRAB criteria and newer SLiM biomarkers.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2005

    Multiple Myeloma International Staging System (ISS)

    The Multiple Myeloma International Staging System (ISS) is indicated for bedside clinical practice to support Prognosticates severity of multiple myeloma based on routinely obtained lab values including serum β2 microglobulin and albumin levels.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2016

    Multiple Myeloma Response Criteria (IMWG)

    The Multiple Myeloma Response Criteria (IMWG) is indicated for bedside clinical practice to support Evaluates disease response in multiple myeloma according to International Myeloma Working Group (IMWG) criteria including Complete Response, Partial Response, and Progressive Disease categories.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2017

    Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSEC-PM)

    The Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSEC-PM) is indicated for bedside clinical practice to support Predicts survival in patients with myelofibrosis secondary to polycythemia vera (PV) and essential thrombocythemia (ET). This specialized prognostic model was developed specifically for secondary myelofibrosis, incorporating clinical parameters and molecular genetic information to provide superior risk stratification compared to models designed for primary myelofibrosis.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2014

    National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI)

    The National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) is indicated for bedside clinical practice to support Predicts survival in patients with diffuse large B-cell lymphoma (DLBCL) using age, LDH levels, extranodal involvement, Ann Arbor stage, and ECOG performance status. Developed for the rituximab era with enhanced prognostic discrimination.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2001

    Neutrophil-Lymphocyte Ratio (NLR) Calculator

    The Neutrophil-Lymphocyte Ratio (NLR) Calculator is indicated for bedside clinical practice to support Calculates neutrophil-lymphocyte ratio. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2017

    PLASMIC Score — TTP Risk Stratification

    The PLASMIC Score — TTP Risk Stratification is indicated for bedside clinical practice to support The PLASMIC score predicts severe ADAMTS13 deficiency in suspected thrombotic thrombocytopenic purpura. 7 items, 1 point each. Total 0-7.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology

    Platelet-to-Lymphocyte Ratio (PLR)

    The Platelet-to-Lymphocyte Ratio (PLR) is indicated for bedside clinical practice to support PLR is a systemic inflammation marker: platelets divided by lymphocytes (same units). Reported as a continuous value; no single validated cutoff.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2013

    Polycythemia Vera Thrombosis Risk

    The Polycythemia Vera Thrombosis Risk is indicated for bedside clinical practice to support ELN/Tefferi risk stratification for thrombosis in polycythemia vera: high risk if age >= 60 or prior thrombosis.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2015

    Revised International Staging System (R-ISS) for Multiple Myeloma

    The Revised International Staging System (R-ISS) for Multiple Myeloma is indicated for bedside clinical practice to support Myeloma staging combining ISS, LDH and high-risk cytogenetics.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2024

    Corrected Reticulocyte Percentage/Reticulocyte Production Index (RPI)

    The Corrected Reticulocyte Percentage/Reticulocyte Production Index (RPI) is indicated for bedside clinical practice to support Assesses bone marrow response to anemia by correcting reticulocyte count for degree of anemia and maturation time. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology

    Soluble Transferrin Receptor / Ferritin Index

    The Soluble Transferrin Receptor / Ferritin Index is indicated for bedside clinical practice to support sTfR/log(ferritin) index helps distinguish iron deficiency from anemia of chronic disease.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology1962

    Total Blood Volume (Nadler)

    The Total Blood Volume (Nadler) is indicated for bedside clinical practice to support Estimates total blood volume (BV) in adults using the Nadler formula (1962): sex-specific equations from height (m) and weight (kg). Result in liters; multiply by 1000 for mL.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematologystandard

    Transferrin Saturation

    The Transferrin Saturation is indicated for bedside clinical practice to support Transferrin saturation for iron deficiency evaluation.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • HematologyVillalta 1994

    Villalta Score for Post-thrombotic Syndrome (PTS)

    The Villalta Score for Post-thrombotic Syndrome (PTS) is indicated for bedside clinical practice to support Diagnoses and stratifies severity of post-thrombotic syndrome in patients with history of deep venous thrombosis (DVT). The score combines patient-reported symptoms with physician-assessed clinical signs to provide standardized PTS evaluation.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2020

    VTE-BLEED Score

    The VTE-BLEED Score is indicated for bedside clinical practice to support Assesses bleeding risk on anticoagulation therapy in patients with venous thromboembolism (VTE). This validated risk score enables better stratification of bleeding risk during stable anticoagulation after a first VTE episode. Unlike bleeding risk scores derived from atrial fibrillation patients, the VTE-BLEED score is specifically designed for VTE patients who have different comorbidity profiles and risk factors.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2016

    WHO Diagnostic Criteria for Polycythemia Vera (2016)

    The WHO Diagnostic Criteria for Polycythemia Vera (2016) is indicated for bedside clinical practice to support World Health Organization 2016 diagnostic criteria for polycythemia vera. Requires 3 major criteria OR 2 major criteria + 1 minor criterion for diagnosis. Designed to detect masked polycythemia vera cases missed by previous 2008 criteria.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Hematology2016

    WHO Diagnostic Criteria for Systemic Mastocytosis (2016)

    The WHO Diagnostic Criteria for Systemic Mastocytosis (2016) is indicated for bedside clinical practice to support World Health Organization 2016 diagnostic criteria for systemic mastocytosis. Requires 1 major criterion + 1 minor criterion OR 3 minor criteria for diagnosis. Used to distinguish systemic mastocytosis from cutaneous mastocytosis and other mast cell disorders.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • HematologyMalcovati 2007

    WPSS (WHO classification-based Prognostic Scoring System) for Myelodysplastic Syndrome

    The WPSS (WHO classification-based Prognostic Scoring System) for Myelodysplastic Syndrome is indicated for bedside clinical practice to support Assesses prognosis of patients with myelodysplastic syndrome (MDS) based on WHO morphological classification, cytogenetics, and transfusion requirement. The WPSS provides dynamic prognostic assessment throughout disease course and stratifies patients into five risk groups.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
D
Dexamed|دگزامد

ماشین‌حساب‌های بالینی و ابزارهای تصمیم‌یار پزشکی هوشمند برای کادر درمان و دانشجویان علوم پزشکی.

ابزارهای بالینی

  • همه ماشین‌حساب‌های پزشکی
  • ماشین‌حساب‌های برگزیده من
  • صفحه اصلی پلتفرم دگزامد

پلتفرم

  • سامانه بین‌المللی DexaMed AI
  • ورود به پنل مدیریت
  • درباره ماشین‌حساب‌ها

سلب مسئولیت پزشکی

ماشین‌حساب‌های دگزامد صرفاً ابزار کمک‌تصمیم بالینی هستند و جایگزین قضاوت تخصصی و معاینه پزشک معالج محسوب نمی‌شوند.

© 2026 دگزامد — تمام حقوق محفوظ است.

مجموعه ماشین‌حساب‌ها و امتیازهای تشخیصی-بالینی دگزامد